Skip to main content

Table 3 Treatment-emergent changes in blood pressure and pulse

From: A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

Category Galcanezumab 120 mg Galcanezumab 240 mg
N n (%) N n (%)
Elevated BP and pulse
 Sitting SBP ≥140 mmHg and ≥ 20 mmHg increase from baseline 120 5 (4.2) 124 4 (3.2)
 Sitting DBP ≥90 mmHg and ≥ 10 mmHg increase from baseline 116 6 (5.2) 126 16 (12.7)*
 Sitting pulse > 100 bpm and ≥ 15 bpm increase from baseline 129 3 (2.3) 139 5 (3.6)
Sustained elevation at 2 consecutive visits
 Sitting SBP 119 1 (0.8) 119 1 (0.8)
 Sitting DBP 115 2 (1.7) 121 2 (1.7)
 Sitting pulse 128 0 133 3 (2.3)
Potentially clinically significant elevation at anytime
 Sitting SBP ≥180 mmHg and ≥ 20 mmHg increase from baseline 129 0 139 0
 Sitting DBP ≥105 mmHg and ≥ 15 mmHg increase from baseline 129 1 (0.8) 138 1 (0.7)
  1. BP blood pressure, DBP diastolic blood pressure, SBP systolic blood pressure
  2. *P < .05
\